Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTaP-IPV combined vaccine · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DTaP-IPV combined vaccine | BIOLOGICAL | 0.5 mL, IM |
| DTaP vaccine | BIOLOGICAL | 0.5 mL, IM |
Inclusion Criteria: * Aged 56 to 70 days inclusive on the day of inclusion * Born at full term pregnancy (\>37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedu...
The DTaP-IPV combined vaccine is a vaccine developed by Sanofi that combines protection against diphtheria, tetanus, pertussis, and poliomyelitis in a single product. It is given to infants and young children, with trial enrollment starting at 56 days of age. It is being studied for use in infectious disease prevention.
The DTaP-IPV combined vaccine is used to protect against pertussis, diphtheria, tetanus, and poliomyelitis. Sanofi is developing it as a single combined immunization for these four diseases. The Phase 3 trial enrolled healthy infants from 56 days of age in South Korea.
Sanofi makes the DTaP-IPV combined vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is the developer of this combined pediatric vaccine candidate.
The DTaP-IPV combined vaccine is in Phase 3 clinical development. It is an investigational vaccine and is not described as approved. One Phase 3 trial has been completed, and no trials are currently active.
The DTaP-IPV combined vaccine has been studied in one completed Phase 3 trial, NCT00319852, titled Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV. That randomized, active-controlled trial enrolled 442 healthy participants in South Korea, with ages starting at 56 days.